Insulet Corporation $PODD Holdings Boosted by Aster Capital Management DIFC Ltd

Aster Capital Management DIFC Ltd raised its position in shares of Insulet Corporation (NASDAQ:PODD) by 1,015.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,979 shares of the medical instruments supplier’s stock after acquiring an additional 2,712 shares during the period. Aster Capital Management DIFC Ltd’s holdings in Insulet were worth $920,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of PODD. Handelsbanken Fonder AB grew its holdings in shares of Insulet by 16.0% during the third quarter. Handelsbanken Fonder AB now owns 21,016 shares of the medical instruments supplier’s stock valued at $6,488,000 after buying an additional 2,900 shares in the last quarter. Generali Investments Management Co LLC boosted its position in Insulet by 300.6% during the 3rd quarter. Generali Investments Management Co LLC now owns 701 shares of the medical instruments supplier’s stock worth $216,000 after acquiring an additional 526 shares during the period. Andra AP fonden grew its stake in Insulet by 50.0% during the 3rd quarter. Andra AP fonden now owns 86,400 shares of the medical instruments supplier’s stock valued at $26,674,000 after acquiring an additional 28,800 shares in the last quarter. Diversify Wealth Management LLC grew its stake in Insulet by 5.6% during the 3rd quarter. Diversify Wealth Management LLC now owns 4,782 shares of the medical instruments supplier’s stock valued at $1,525,000 after acquiring an additional 254 shares in the last quarter. Finally, Xponance Inc. increased its holdings in shares of Insulet by 1.0% in the 3rd quarter. Xponance Inc. now owns 16,692 shares of the medical instruments supplier’s stock valued at $5,153,000 after purchasing an additional 158 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PODD. Leerink Partners decreased their price target on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Canaccord Genuity Group cut their target price on shares of Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Evercore set a $340.00 target price on shares of Insulet in a research note on Thursday, February 19th. Zacks Research downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Finally, The Goldman Sachs Group cut their price objective on Insulet from $363.00 to $326.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $354.57.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.39% of the company’s stock.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $251.50 on Friday. The stock has a market capitalization of $17.71 billion, a P/E ratio of 71.86, a P/E/G ratio of 1.48 and a beta of 1.41. The business has a 50-day moving average of $269.07 and a two-hundred day moving average of $303.58. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million for the quarter, compared to the consensus estimate of $768.31 million. During the same period last year, the business earned $1.15 EPS. The firm’s revenue was up 31.2% compared to the same quarter last year. On average, equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.